Literature DB >> 21149439

Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production.

Anne Hamacher-Brady1, Henning A Stein, Simon Turschner, Ina Toegel, Rodrigo Mora, Nina Jennewein, Thomas Efferth, Roland Eils, Nathan R Brady.   

Abstract

The antimalarial agent artesunate (ART) activates programmed cell death (PCD) in cancer cells in a manner dependent on the presence of iron and the generation of reactive oxygen species. In malaria parasites, ART cytotoxicity originates from interactions with heme-derived iron within the food vacuole. The analogous digestive compartment of mammalian cells, the lysosome, similarly contains high levels of redox-active iron and in response to specific stimuli can initiate mitochondrial apoptosis. We thus investigated the role of lysosomes in ART-induced PCD and determined that in MCF-7 breast cancer cells ART activates lysosome-dependent mitochondrial outer membrane permeabilization. ART impacted endolysosomal and autophagosomal compartments, inhibiting autophagosome turnover and causing perinuclear clustering of autophagosomes, early and late endosomes, and lysosomes. Lysosomal iron chelation blocked all measured parameters of ART-induced PCD, whereas lysosomal iron loading enhanced death, thus identifying lysosomal iron as the lethal source of reactive oxygen species upstream of mitochondrial outer membrane permeabilization. Moreover, lysosomal inhibitors chloroquine and bafilomycin A1 reduced ART-activated PCD, evidencing a requirement for lysosomal function during PCD signaling. ART killing did not involve activation of the BH3-only protein, Bid, yet ART enhanced TNF-mediated Bid cleavage. We additionally demonstrated the lysosomal PCD pathway in T47D and MDA-MB-231 breast cancer cells. Importantly, non-tumorigenic MCF-10A cells resisted ART-induced PCD. Together, our data suggest that ART triggers PCD via engagement of distinct, interconnected PCD pathways, with hierarchical signaling from lysosomes to mitochondria, suggesting a potential clinical use of ART for targeting lysosomes in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21149439      PMCID: PMC3057810          DOI: 10.1074/jbc.M110.210047

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  77 in total

Review 1.  Lysosomes and autophagy in cell death control.

Authors:  Guido Kroemer; Marja Jäättelä
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

Review 2.  Bid, a BH3-only multi-functional molecule, is at the cross road of life and death.

Authors:  Xiao-Ming Yin
Journal:  Gene       Date:  2006-01-27       Impact factor: 3.688

3.  Apoptosis of human umbilical vein endothelial cells induced by artesunate.

Authors:  Guo-Dong Wu; Hui-Jun Zhou; Xiu-Hua Wu
Journal:  Vascul Pharmacol       Date:  2004-07       Impact factor: 5.773

4.  Artesunate in the treatment of metastatic uveal melanoma--first experiences.

Authors:  Thomas G Berger; Detlef Dieckmann; Thomas Efferth; Erwin S Schultz; Jens-Oliver Funk; Andreas Baur; Gerold Schuler
Journal:  Oncol Rep       Date:  2005-12       Impact factor: 3.906

5.  Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.

Authors:  Thomas Efferth; Manfred Volm
Journal:  In Vivo       Date:  2005 Jan-Feb       Impact factor: 2.155

6.  Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite.

Authors:  A V Pandey; B L Tekwani; R L Singh; V S Chauhan
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

7.  Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells.

Authors:  Min Lu; Rafael Mira-y-Lopez; Shigeo Nakajo; Kazuyasu Nakaya; Yongkui Jing
Journal:  Oncogene       Date:  2005-06-23       Impact factor: 9.867

8.  Effects of artemisinin-tagged holotransferrin on cancer cells.

Authors:  Henry Lai; Tomikazu Sasaki; Narendra P Singh; Archna Messay
Journal:  Life Sci       Date:  2004-11-23       Impact factor: 5.037

9.  Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate.

Authors:  Raffaella Dell'Eva; Ulrich Pfeffer; Roberta Vené; Luca Anfosso; Alessandra Forlani; Adriana Albini; Thomas Efferth
Journal:  Biochem Pharmacol       Date:  2004-12-15       Impact factor: 5.858

10.  Kinesin-2 is a motor for late endosomes and lysosomes.

Authors:  Christa L Brown; Kerstin C Maier; Tobias Stauber; Laura M Ginkel; Linda Wordeman; Isabelle Vernos; Trina A Schroer
Journal:  Traffic       Date:  2005-12       Impact factor: 6.215

View more
  69 in total

Review 1.  Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones.

Authors:  Yulin Ren; Jianhua Yu; A Douglas Kinghorn
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

2.  Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.

Authors:  Blake S Moses; Samantha McCullough; Jennifer M Fox; Bryan T Mott; Søren M Bentzen; MinJung Kim; Jeffrey W Tyner; Rena G Lapidus; Ashkan Emadi; Michelle A Rudek; Tami J Kingsbury; Curt I Civin
Journal:  Blood Adv       Date:  2021-02-09

3.  Induction of Apoptosis in Human Breast Cancer MCF-7 Cells by a Semi-Synthetic Derivative of Artemisinin: A Caspase-Related Mechanism.

Authors:  Leila Jamalzadeh; Hossein Ghafoori; Mahmoodreza Aghamaali; Reyhaneh Sariri
Journal:  Iran J Biotechnol       Date:  2017-09-27       Impact factor: 1.671

4.  Artesunate and its emerging anti-neoplastic effects: beyond its role in attenuating tumor growth in osteosarcomas.

Authors:  Shailendra Kapoor
Journal:  J Zhejiang Univ Sci B       Date:  2012-12       Impact factor: 3.066

5.  Development and Evaluation of Artesunate-Loaded Chitosan-Coated Lipid Nanocapsule as a Potential Drug Delivery System Against Breast Cancer.

Authors:  Tuan Hiep Tran; Tuan Duc Nguyen; Bijay Kumar Poudel; Hanh Thuy Nguyen; Jong Oh Kim; Chul Soon Yong; Chien Ngoc Nguyen
Journal:  AAPS PharmSciTech       Date:  2015-03-19       Impact factor: 3.246

Review 6.  Updates on artemisinin: an insight to mode of actions and strategies for enhanced global production.

Authors:  Neha Pandey; Shashi Pandey-Rai
Journal:  Protoplasma       Date:  2015-03-27       Impact factor: 3.356

7.  Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.

Authors:  Mahadeo A Sukhai; Swayam Prabha; Rose Hurren; Angela C Rutledge; Anna Y Lee; Shrivani Sriskanthadevan; Hong Sun; Xiaoming Wang; Marko Skrtic; Ayesh Seneviratne; Maria Cusimano; Bozhena Jhas; Marcela Gronda; Neil MacLean; Eunice E Cho; Paul A Spagnuolo; Sumaiya Sharmeen; Marinella Gebbia; Malene Urbanus; Kolja Eppert; Dilan Dissanayake; Alexia Jonet; Alexandra Dassonville-Klimpt; Xiaoming Li; Alessandro Datti; Pamela S Ohashi; Jeff Wrana; Ian Rogers; Pascal Sonnet; William Y Ellis; Seth J Corey; Connie Eaves; Mark D Minden; Jean C Y Wang; John E Dick; Corey Nislow; Guri Giaever; Aaron D Schimmer
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

Review 8.  Potential applications of artemisinins in ocular diseases.

Authors:  Bing-Wen Lu; Li-Ke Xie
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

9.  Evaluation of artemisinins for the treatment of acute myeloid leukemia.

Authors:  Christina D Drenberg; Jassada Buaboonnam; Shelley J Orwick; Shuiying Hu; Lie Li; Yiping Fan; Anang A Shelat; R Kiplin Guy; Jeffrey Rubnitz; Sharyn D Baker
Journal:  Cancer Chemother Pharmacol       Date:  2016-04-28       Impact factor: 3.333

10.  Chronic Iron Limitation Confers Transient Resistance to Oxidative Stress in Marine Diatoms.

Authors:  Shiri Graff van Creveld; Shilo Rosenwasser; Yishai Levin; Assaf Vardi
Journal:  Plant Physiol       Date:  2016-08-08       Impact factor: 8.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.